Mandate

Vinge advises Medicover in relation to its listing on Nasdaq Staockholm

Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”), which is wholly owned by the charitable foundation the Jonas and Christina af Jochnick Foundation, in relation to Medicover’s listing on Nasdaq Stockholm.

Trading in Medicover’s B share on Nasdaq Stockholm commences today, 23 May 2017. The price in the offering was set at SEK 56 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 7.5 billion. Assuming full exercise of the over-allotment option in the offering, the value of the offering will amount to approximately SEK 2.3 billion.

Medicover is a leading international healthcare and diagnostic services provider in Poland, Germany, Romania, Ukraine and certain other markets, primarily in Central and Eastern Europe (“CEE”). Additionally, Medicover is in the process of entering the fast-growing Indian healthcare market in order to expand its geographical footprint and further leverage its emerging markets capabilities. Medicover offers a broad range of healthcare services and a significant hub-and-spoke diagnostic laboratory network, supported by extensively developed proprietary software and information systems infrastructure. Medicover operates through two divisions: Healthcare Services and Diagnostic Services.

Vinge’s team primarily consists of Dain Hård Nevonen, Erik Sjöman, Ludvig Frithiof, Sofie Bjärtun, Louise Nordkvist and Astrid Karlsson.

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025